LILRB4

Antengene Presents Four Preclinical Posters at AACR 2024

Retrieved on: 
Saturday, April 6, 2024
PRMT5, AML, CDX, Risk, Weight loss, LILRB4, MTAP, Acute myeloid leukemia, CRS, Cancer, IND, AACR, PDX, Antibody, DDI, TCE, Immunohistochemistry, San Diego Convention Center, Cytokine release syndrome, Vaccine

SHANGHAI and HONG KONG, April 5, 2024 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cancer, today announced the presentation of four preclinical posters at the 2024 American Association for Cancer Research Annual Meeting (AACR 2024), taking place from April 5th to April 10th at the San Diego Convention Center in San Diego, California, the United States.

Key Points: 
  • SHANGHAI and HONG KONG, April 5, 2024 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cancer, today announced the presentation of four preclinical posters at the 2024 American Association for Cancer Research Annual Meeting (AACR 2024), taking place from April 5th to April 10th at the San Diego Convention Center in San Diego, California, the United States.
  • Study results showed that ATG-042 has the potential to elegantly target tumor cells while sparing healthy cells, with an attractive developability profile.
  • 12:00 AM - 3:30 AM, April 10, 2024 (Beijing Time)
    This preclinical study was designed to test the in vitro/in vivo efficacy, and preclinical pharmacokinetic (PK) properties of ATG-042.
  • This poster presents the discovery and validation of a novel, highly sensitive immunohistochemistry (IHC) antibody that selectively identifies CLDN18.2.

Biond Biologics Announces Presentation of BND-35, a Novel Anti-ILT3 Antibody for Remodeling the Tumor Microenvironment, at the American Association for Cancer Research (AACR) 2024 Annual Meeting

Retrieved on: 
Tuesday, March 26, 2024
TME, Cancer, EGFR, Ligand, Patient, ILT3, Research, Tumor microenvironment, LILRB4, AACR, Myelocyte, Immunoglobulin G, San Diego Convention Center, NK, Pharmaceutical industry

MISGAV, Israel, March 26, 2024 /PRNewswire/ -- Biond Biologics Ltd., a pioneering clinical-stage biopharmaceutical company, developing innovative immunotherapies for cancer and a transformative platform for the intracellular delivery of biologics, is excited to announce that our BND-35 program has been selected for presentation at the esteemed American Association for Cancer Research (AACR) Annual Meeting, scheduled for April 5 - 10, 2024, in San Diego Convention Center, San Diego, CA, USA. BND-35 is distinguished as a humanized IgG4, ILT3 (LILRB4) antagonist antibody, designed to modulate the tumor microenvironment (TME) from immunosuppressive to pro-inflammatory, thereby counteracting tumor growth. BND-35 phase 1 trial includes a unique clinical design, that will be presented in the ACCR, and is based on Biond's extensive pre-clinical work and the ability of BND-35 to block interactions with the various ligands of ILT3.

Key Points: 
  • BND-35 is distinguished as a humanized IgG4, ILT3 (LILRB4) antagonist antibody, designed to modulate the tumor microenvironment (TME) from immunosuppressive to pro-inflammatory, thereby counteracting tumor growth.
  • The presentation, titled "BND-35, a novel anti-ILT3 antibody for remodulation of the tumor microenvironment", will be part of the session on "Immune Targets and Therapies."
  • Biond Biologics' pivotal research on BND-35 demonstrates its specificity in binding ILT3 with high affinity, without affecting other ILT-family receptors.
  • The presentation will underscore Biond's commitment to groundbreaking research and development, aiming to unlock new pathways for cancer treatment.

Immune-Onc Therapeutics Announces Orphan Drug Designation Granted by US FDA for IO-202 (Anti-LILRB4) for the Treatment of Chronic Myelomonocytic Leukemia (CMML)

Retrieved on: 
Wednesday, February 21, 2024
Oncology, Health, FDA, General Health, Clinical Trials, Pharmaceutical, Biotechnology, AZA, AML, LILRB4, Azacitidine, Marketing, Food, Inflammation, HMA, Therapy, Bone marrow, CMML, Patient, Autoimmunity, Chronic myelomonocytic leukemia, Diagnosis, Acute myeloid leukemia, Pharmaceutical industry

Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a clinical-stage biopharmaceutical company advancing novel therapies in immunology and oncology by targeting myeloid cell inhibitory receptors, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for IO-202 for the treatment of chronic myelomonocytic leukemia (CMML).

Key Points: 
  • Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a clinical-stage biopharmaceutical company advancing novel therapies in immunology and oncology by targeting myeloid cell inhibitory receptors, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for IO-202 for the treatment of chronic myelomonocytic leukemia (CMML).
  • IO-202 received Fast Track Designation for treatment of relapsed or refractory CMML in 2023.
  • In addition, Fast Track and Orphan Drug Designations for IO-202 were granted by the FDA for the treatment of acute myeloid leukemia (AML) in 2022 and 2020, respectively.
  • “We are very proud that the FDA has granted IO-202 Orphan Drug Designation for the treatment of CMML.

Immune-Onc Therapeutics Presents IO-202 Phase 1 Data in Patients with Relapsed or Refractory AML and CMML at the EHA Annual Meeting 2023

Retrieved on: 
Thursday, June 8, 2023
Oncology, Health, FDA, General Health, Clinical Trials, Pharmaceutical, Biotechnology, CMML, AZA, Myelocyte, PD, European Hematology Association, LILRB4, Associate professor, ILT3, Acute leukemia, Chronic myelomonocytic leukemia, Bone marrow, Pharmacokinetics, Fast track (FDA), Acute myeloid leukemia, MD Anderson Cancer Center, MSCE, AML, Azacitidine, Monocyte, Pancreatic serous cystadenoma, MD, Patient, Immunoglobulin G, Division, University, Cure, Blood, EHA, Toxic leukoencephalopathy, Leukemia, Therapy, Safety, Vaccine, Pharmaceutical industry, Rare-earth element

Data from the dose escalation part of the Phase 1 study evaluating patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) and chronic myelomonocytic leukemia (CMML) will be presented during a poster session at the European Hematology Association (EHA) Annual Meeting in Frankfurt, Germany on June 9, 2023.

Key Points: 
  • Data from the dose escalation part of the Phase 1 study evaluating patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) and chronic myelomonocytic leukemia (CMML) will be presented during a poster session at the European Hematology Association (EHA) Annual Meeting in Frankfurt, Germany on June 9, 2023.
  • “AML is the most common form of acute leukemia in adults in the U.S. and is characterized by high rates of relapsed and refractory disease.
  • Monocytic AML is especially in need of break-through medicine as it is often resistant to standard-of-care treatment.
  • Poster presentation details are as follows:
    Title: A first-in-human Phase 1 study of IO-202 (anti-LILRB4 mAb) in Acute Myeloid Leukemia (AML) with monocytic differentiations and Chronic Myelomonocytic Leukemia (CMML) patients.

Immune-Onc Therapeutics to Present Encouraging Phase 1 Data for IO-108 at AACR Annual Meeting 2023

Retrieved on: 
Friday, April 14, 2023
Health, Clinical Trials, General Health, Research, Pharmaceutical, Science, Myelocyte, AACR, PD, LILRB2, LILRB4, CD3, ILT3, Merkel-cell carcinoma, Pharmacokinetics, American Association for Cancer Research, Biomarker, Immunotherapy, ILT4, Patient, Pembrolizumab, Therapy, Disease, Safety, Tislelizumab, Vaccine, Pharmaceutical industry, Angela Merkel

The data will be presented in an oral session at the American Association for Cancer Research (AACR) Annual Meeting in Orlando, Florida, April 18.

Key Points: 
  • The data will be presented in an oral session at the American Association for Cancer Research (AACR) Annual Meeting in Orlando, Florida, April 18.
  • Preclinical data for IO-312, a novel bispecific antibody targeting LILRB4 (ILT3) and CD3 (LILRB4 x CD3) will also be presented on April 18 as a late-breaking poster at AACR 2023.
  • Treatment with IO-108 was well-tolerated to the maximum administered dose (1800 mg Q3W); the maximum tolerated dose was not reached.
  • These findings suggest that LILRB2 is a critically important immunotherapy target.”
    The initial data from dose escalation supports further development of IO-108.

Immune-Onc Therapeutics Announces IO-108 Phase I Clinical Trial Results Selected for Oral Presentation at AACR Annual Meeting 2023

Retrieved on: 
Tuesday, March 14, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, AACR, CD3, Drug development, Therapy, LILRB2, ILT4, American Association for Cancer Research, Patient, Immunotherapy, LILRB4, ILT3, Vaccine, Pharmaceutical industry

In addition, preclinical data for IO-312, a novel bispecific antibody targeting LILRB4 (ILT3) and CD3 (LILRB4 x CD3) will be presented as a late-breaking poster at AACR 2023.

Key Points: 
  • In addition, preclinical data for IO-312, a novel bispecific antibody targeting LILRB4 (ILT3) and CD3 (LILRB4 x CD3) will be presented as a late-breaking poster at AACR 2023.
  • “We are very excited that our interim clinical data of IO-108 is selected for oral presentation at AACR 2023.
  • This reflects the clinical significance and broad market potential of IO-108 as monotherapy and in combination with an anti-PD-1 for treatment in a variety of solid tumors.
  • Presenter: Charlene Liao, Ph.D., chief executive officer of Immune-Onc Therapeutics, Inc

BriSTAR Immunotech To Present its Novel Cell Therapy for Acute Myeloid Leukemia at the AACR Special Conference on AML and MDS

Retrieved on: 
Friday, January 20, 2023
AML, Poster, Date, TCR, STAR, AACR, LILRB4, Acute myeloid leukemia, Myelodysplastic syndrome, American Association for Cancer Research, Pharmaceutical industry

TORONTO, Canada and BEIJING, Jan. 20, 2023 /PRNewswire/ -- BriSTAR Immunotech, a clinical-stage cell therapy company, announced today it will showcase its T-cell receptors (TCR) and antigen receptor (STAR)-T cell therapy technology platform at the American Association for Cancer Research (AACR) special conference on acute myeloid leukemia and myelodysplastic syndrome, taking place January 23-25, 2023, in Austin, Texas.

Key Points: 
  • TORONTO, Canada and BEIJING, Jan. 20, 2023 /PRNewswire/ -- BriSTAR Immunotech, a clinical-stage cell therapy company, announced today it will showcase its T-cell receptors (TCR) and antigen receptor (STAR)-T cell therapy technology platform at the American Association for Cancer Research (AACR) special conference on acute myeloid leukemia and myelodysplastic syndrome, taking place January 23-25, 2023, in Austin, Texas.
  • "The data shows that our LILRB4 STAR-T cell therapy exhibits potent anti-tumor activity against AML in preclinical models," said Dr. James Pan, CEO at BriSTAR Immunotech.
  • "These findings support our strategy to maximize the potential of our unique STAR-T technology platform."
  • Date / Time: Tuesday, January 24, 2023 7:15 - 9:30 p.m. CST
    The complete abstract will be available here .

Immune-Onc Therapeutics Announces Close of Series B Extension Financing, Bringing Total Round to $131 Million

Retrieved on: 
Thursday, January 5, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Cancer, LILRB2, ILT3, Food, Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, LLS, Biomarker, Leukemia, Immunotherapy, ILT4, Leukemia & Lymphoma Society, LILRB4, Growth, Patient, Regeneron Pharmaceuticals, Conference, Tislelizumab, Pharmaceutical industry

Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a private, clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting myeloid checkpoints today announced the close of an additional $25 million through a Series B extension, for a total of $131 million in Series B financing.

Key Points: 
  • Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a private, clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting myeloid checkpoints today announced the close of an additional $25 million through a Series B extension, for a total of $131 million in Series B financing.
  • This extension was led by existing investor Triwise Capital and with participation from new investors including Proxima Ventures, among others.
  • In addition, the company has received continued strategic capital investments from The Leukemia & Lymphoma Society’s Therapy Acceleration Program® (LLS TAP) and Wuxi Biologics HealthCare Venture.
  • Immune-Onc will provide additional corporate and clinical progress updates during 1:1 investor and prospective partner meetings at the upcoming J.P. Morgan 41st Annual Healthcare Conference.

NGM Bio Presents Preliminary Data from Phase 1 Monotherapy Dose Escalation Trial of NGM707 in Patients with Advanced or Metastatic Solid Tumors at 2022 ESMO-IO Annual Meeting

Retrieved on: 
Wednesday, December 7, 2022
Neoplasm, Retina, RO, PR, COVID-19, Pneumonitis, Liver, Tumor microenvironment, Health, Safety, Congress, Cancer, European Society for Medical Oncology, Protein engineering, ILT3, ILT2, GFRAL, Trae tha Truth, Biology, Therapy, LIR, Merck, LILRB4, ILT, RECIST, Translation, Oncology, Disease, Patient, ILT4, ESMO, Linearity, Cell, Failure, LAIR1, NGM, Myelocyte, G5, Merck Sharp & Dohme Federal Credit Union, Part, CD163, Merck & Co., Risk, Pharmaceutical industry, Vaccine

The Phase 1 portion of the ongoing NGM707 trial includes a monotherapy dose escalation arm (Part 1a) and a dose-finding arm in combination with pembrolizumab (KEYTRUDA®) (Part 1b).

Key Points: 
  • The Phase 1 portion of the ongoing NGM707 trial includes a monotherapy dose escalation arm (Part 1a) and a dose-finding arm in combination with pembrolizumab (KEYTRUDA®) (Part 1b).
  • The Phase 2 portion of the trial will include expansion cohorts of patients treated with NGM707 in combination with KEYTRUDA (Part 2b) in several advanced solid tumor types.
  • The Part 1a arm enrolled patients into escalating NGM707 dose cohorts (6 mg to 1800 mg) administered intravenously every three weeks.
  • As of a November 23, 2022 data cut-off, 34 patients have been enrolled in the monotherapy dose escalation.

Jounce Therapeutics Reports Third Quarter 2022 Financial Results

Retrieved on: 
Thursday, November 10, 2022
Investor, European Society for Medical Oncology, Partnership, ICOS, Immunotherapy, Research, Macrophage, Family, G&A, SELECT, Therapy, PD-L1, PD-1, Conference, Society for Immunotherapy of Cancer, ILT4, Security (finance), Review, LILRB4, Marketing, Tumor microenvironment, CCR8, Gilead Sciences, U.S. Securities and Exchange Commission, BTC, Pharmacokinetics, Private Securities Litigation Reform Act, Cancer, Patient, COVID-19, LILRB2, Webcast, Oncology, Neoplasm, HNSCC, Myelocyte, Public expenditure, Poster, Society, Congress, POC, GLOBE, PFS, Head, Intellectual property, Investment, ESMO, Cholangiocarcinoma, Annual report, NASDAQ, Safety, ILT3, Immune system, Heart, Squamous cell carcinoma, SITC, Life insurance, Pharmaceutical industry, Vaccine, IND, Fourth, fifth, and sixth derivatives of position

- Ended the quarter with $130.3 million in cash, cash equivalents and investments -

Key Points: 
  • - Ended the quarter with $130.3 million in cash, cash equivalents and investments -
    CAMBRIDGE, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today reported financial results for the third quarter ended September 30, 2022 and provided a corporate update.
  • Third Quarter 2022 Financial Results:
    Cash position: As of September 30, 2022, cash, cash equivalents and investments decreased to $130.3 million, compared to $220.2 million as of December 31, 2021.
  • License and collaboration revenue: Jounce did not recognize any revenue during the third quarter of 2022 or 2021.
  • Based on its current operating and development plans and cost containment efforts, Jounce is reiterating its financial guidance for 2022.